Clinical Trial

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

Study acronym: MARITIME-3-J
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-05-15; most recent amendment 2025-12-15.
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Status change: Not Yet Recruiting → Recruiting 2025-06-24
Trial Details
NCT Number NCT06987695
Lead Sponsor Amgen
Conditions Obesity Disease
Enrollment 279 participants
Start Date 2025-06-13
Primary Completion 2027-04-27 (estimated)
Study Completion 2027-07-21 (estimated)
Updated on ClinicalTrials.gov 2025-12-17